- Home
- HBB vs ADCT Comparison
HBB vs ADCT Comparison
Compare HBB & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- ADCT
- Stock Information
- Founded
- HBB 1904
- ADCT 2011
- Country
- HBB United States
- ADCT Switzerland
- Employees
- HBB N/A
- ADCT 274
- Industry
- HBB Home Furnishings
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- ADCT Health Care
- Exchange
- HBB Nasdaq
- ADCT Nasdaq
- Market Cap
- HBB 292.6M
- ADCT 224.3M
- IPO Year
- HBB 2017
- ADCT 2020
- Fundamental
- Price
- HBB $19.96
- ADCT $2.27
- Analyst Decision
- HBB
- ADCT Strong Buy
- Analyst Count
- HBB 0
- ADCT 5
- Target Price
- HBB N/A
- ADCT $7.33
- AVG Volume (30 Days)
- HBB 64.7K
- ADCT 460.5K
- Earning Date
- HBB 10-30-2024
- ADCT 11-07-2024
- Dividend Yield
- HBB 2.31%
- ADCT N/A
- EPS Growth
- HBB 107.04
- ADCT N/A
- EPS
- HBB 1.88
- ADCT N/A
- Revenue
- HBB $647,834,000.00
- ADCT $70,717,000.00
- Revenue This Year
- HBB $4.60
- ADCT $6.38
- Revenue Next Year
- HBB N/A
- ADCT $11.73
- P/E Ratio
- HBB $10.32
- ADCT N/A
- Revenue Growth
- HBB 5.30
- ADCT N/A
- 52 Week Low
- HBB $14.34
- ADCT $0.94
- 52 Week High
- HBB $31.78
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- HBB 32.97
- ADCT 42.52
- Support Level
- HBB $18.62
- ADCT $1.91
- Resistance Level
- HBB $20.11
- ADCT $2.46
- Average True Range (ATR)
- HBB 0.97
- ADCT 0.22
- MACD
- HBB 0.24
- ADCT 0.01
- Stochastic Oscillator
- HBB 39.68
- ADCT 38.33
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.